Business Wire
26 Apr 2026, 23:51 UTC · 27w ago
Verdict
Headline takes no side. We score OGN +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 74% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
What the story claims
3 claims · scored −1 bearish … +1 bullish
Sun Pharma will acquire all outstanding shares of Organon for US$14.00 per share in an all-cash transaction.
So whatA definitive all-cash acquisition at a fixed price creates an immediate and highly certain price target for Organon shares, heavily moving its stock toward the offer price.
More positive than 99% of claims this week
Sun Pharma will acquire Organon, expanding its portfolio and global market footprint.
Continue reading
5 related stories
More positive than 93% of claims this week
Sun Pharma is using an all-cash transaction structure to fund the acquisition of Organon.
So whatAn all-cash deal requires Sun Pharma to deploy or borrow significant capital, increasing balance sheet leverage and impacting its cash reserves, which is a headwind for the acquirer's stock.
More negative than 90% of claims this week
Which stocks this story touches
More positive than 74% of ticker scores this week
The company is being acquired in an all-cash transaction at a specific share price.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
2h ago
+23.2%
Price agrees with the score
$13.87 vs $11.26 close before publication (Apr 24) · not market-adjusted
OGN chart →
